What is the Market's View on Titan Pharmaceuticals, Inc. common stock (TTNP) Stock's Price and Volume Trends Thursday?

Thursday, October 06, 2022 01:17 PM | InvestorsObserver Analysts

Mentioned in this article

What is the Market's View on Titan Pharmaceuticals, Inc. common stock (TTNP) Stock's Price and Volume Trends Thursday?

Titan Pharmaceuticals, Inc. common stock (TTNP) stock has risen 8.49% over the past week and gets a Neutral rating from InvestorsObserver Sentiment Indicator.

Titan Pharmaceuticals, Inc. common stock has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on TTNP!

See Full TTNP Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With TTNP Stock Today?

Titan Pharmaceuticals, Inc. common stock (TTNP) stock is higher by 4.55% while the S&P 500 has fallen -0.52% as of 12:37 PM on Thursday, Oct 6. TTNP has risen $0.05 from the previous closing price of $1.10 on volume of 19,003 shares. Over the past year the S&P 500 is lower by -13.40% while TTNP has fallen -35.75%. TTNP lost -$0.87 per share in the over the last 12 months.

More About Titan Pharmaceuticals, Inc. common stock

Titan Pharmaceuticals Inc is a pharmaceutical company developing therapeutics utilizing its proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases for which steady state delivery of a drug provides efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. Its first product based on ProNeura technology was the Probuphine (buprenorphine) implant, which was approved in the United States, Canada and the European Union, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine. Click Here to get the full Stock Report for Titan Pharmaceuticals, Inc. common stock stock.